Abstract: A cylindrical workpiece with a helical axial groove allowing for centerless grinding which has an angular overlap around the outer circumference on the body of the workpiece. The angular overlap ensures continuous tangential contact with the grinding wheels as the workpiece is rotated.

Abstract: A method for magnetic resonance imaging includes performing a pre-scan using a spin-echo diffusion acquisition with a one-time MRI pulse sequence to measure phase differences between diffusion and non-diffusion acquisitions, which correspond to an estimation of eddy-current-induced phase in a diffusion-prepared sequence; and performing a scan using arbitrary waveform shim currents applied to a shim array during the acquisition, wherein the shim currents are determined from the measured phase differences from the pre-scan to create opposite phase maps to compensate eddy-current or system-imperfection-induced phase differences; wherein the scan and pre-scan are performed using an MRI apparatus with a channel integrated receiver and the shim array.

Abstract: A variable cam timing phaser of a variable cam timing system includes a housing and a rotor moveable with respect to the housing. The rotor and the housing define advance and retard chambers. The variable cam timing phaser also includes a control valve assembly. The control valve assembly includes a valve housing defining a valve housing interior, a supply port, first and second working ports, and an exhaust port. The control valve assembly also includes a piston moveable for controlling flow of the hydraulic fluid through the valve housing interior. The exhaust port is fluidly connectable with a sump through a vent path that is defined by at least one of the valve housing and the rotor. The vent path is configured to prevent air from being sucked into the variable cam timing phaser through the vent path.

Abstract: A variable cam timing phaser of a variable cam timing system includes a housing and a rotor moveable with respect to the housing. The rotor and the housing define advance and retard chambers. The variable cam timing phaser also includes a control valve assembly. The control valve assembly includes a valve housing defining a valve housing interior, a supply port, first and second working ports, and an exhaust port. The control valve assembly also includes a piston moveable for controlling flow of the hydraulic fluid through the valve housing interior. The exhaust port is fluidly connectable with a sump through a vent path that is defined by at least one of the valve housing and the rotor. The vent path is configured to prevent air from being sucked into the variable cam timing phaser through the vent path.

Abstract: The invention relates to a combination comprising an effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, and an effective amount of heparin, or a pharmaceutically acceptable salt thereof, for use in treatment of thromboinflammation, such as instant blood-mediated inflammatory reaction (IBMIR) and ischemia-reperfusion injury (IRI). The invention is based on the surprising finding that heparin, or the pharmaceutically acceptable salt thereof, can synergistically boost anti-thromboinflammatory effects of dextran sulfate, or the pharmaceutically acceptable salt thereof.

Abstract: Embodiments disclosed herein relate to methods and systems for performing automated assays, and particularly to performing sequential assays on a sample on an automated instrument.

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in improving liver function in a subject suffering from a non-alcoholic fatty liver disease (NAFLD). The dextran sulfate, or the pharmaceutically acceptable salt thereof, has an average molecular weight equal to or below 10 000 Da and is formulated for intravenous or subcutaneous administration to the subject.

Abstract: Embodiments disclosed herein relate to methods and systems for performing automated assays, and particularly to performing sequential assays on a sample on an automated instrument.

Abstract: A hydraulic variable camshaft timing (VCT) assembly including a stator having at least one fluid chamber; and a rotor, received by and angularly displaceable relative to the stator, having at least one vane positioned within the fluid chamber extending radially outwardly from a hub, and a hydraulic switch assembly positioned in the rotor to regulate a flow of fluid between an advancing chamber and a retarding chamber through the vane.

Abstract: A variable cam timing phaser of a variable cam timing system includes a housing and a rotor moveable with respect to the housing. The rotor and the housing define advance and retard chambers. The variable cam timing phaser also includes a control valve assembly. The control valve assembly includes a valve housing defining a valve housing interior, a supply port, first and second working ports, and an exhaust port. The control valve assembly also includes a piston moveable for controlling flow of the hydraulic fluid through the valve housing interior. The exhaust port is fluidly connectable with a sump through a vent path that is defined by at least one of the valve housing and the rotor. The vent path is configured to prevent air from being sucked into the variable cam timing phaser through the vent path.

Abstract: The present invention is directed towards articles comprising a steroid material comprising a steroid dimer and at least one therapeutic agent distributed throughout the steroid material and the use of such articles in sustained release delivery systems. Said article may be fibers, fiber meshes, woven fabrics, non-woven fabrics, films, pellets, cylinders, microparticles, nanoparticles, shaped articles or coatings on a substrate (such as an implant). Control of the release profile of the at least one therapeutic agent can be achieved via selection of the steroids within the steroid dimer, the linker conjugating the steroids within the dimer, the linkage groups between the steroids and the linker, the surface area of the article, the location of the at least one therapeutic agent within the article and the amount of the at least one therapeutic agent within the article.

Abstract: A variable cam timing phaser has a rotor assembly with a central hub defining an axial bore and an interface groove with a first seal land, a second seal land and a single undercut area. A width of the first seal land is greater than a width of the second seal land. The single undercut area is in fluid communication with an axial undercut passage connected to a radial undercut passage within the rotor assembly. A clamping interface is between the camshaft and the rotor assembly, such that a seal is present between first seal land and the first end of the camshaft, and the second seal land and the first end of the camshaft. Fluid from a supply, flows into the passage of the camshaft to the single undercut area, through the axial undercut passage, the radial undercut passage to a passage within the rotor assembly.

Abstract: The invention relates to the use of dextran sulfate, or a pharmaceutically acceptable salt thereof, in modulating leukocyte activation in allogenic CAR-T cell therapy. Dextran sulfate can be used together with allogenic CAR-T cells to achieve an activation pattern similar to what is obtained in autologous CAR-T cells therapy. Hence, dextran sulfate, or the pharmaceutically acceptable salt thereof, is capable of suppressing unspecific leukocyte activation in connection with allogenic CAR-T cell therapy.

Abstract: The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.

Abstract: The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.

Abstract: Embodiments disclosed herein relate to methods and systems for performing automated assays, and particularly to performing sequential assays on a sample on an automated instrument.

Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Abstract: A variable cam timing phaser mounted to a camshaft and including a housing assembly having an outer circumference for accepting a drive force; a rotor assembly received by the housing assembly defining a chamber separated into an advance chamber and retard chamber by a vane; a control valve in fluid communication with the advance chamber and the retard chamber, a source of fluid, and a sump through at least one exhaust line connected to at least one exhaust port; and at least one check valve in the at least one exhaust line between the control valve and the sump. The at least one check valve prevents air from the sump connected to the at least one exhaust port from being sucked into the variable cam timing phaser through the at least one exhaust port during a torque reversal of the camshaft.